Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
Go back to Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload| (NYSE: BHVN) | Delayed: 15.69 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.69 | 52 Week High | $ | |||
| Open | $15.69 | 52 Week Low | $ | |||
| Day High | $15.69 | P/E | N/A | |||
| Day Low | $15.69 | EPS | $ | |||
| Volume | 7,124 | |||||
